martha_shear

Asking the straightforward question, "How can I be helpful?" is the principle that Michael Torres credits as the foundation of his professional journey. Serving as both the CSO and co-founder of @artan_bio, his commitment recently earned him recognition from Latinos in Bio as an Impacto Awardee. Please join us in sending warm congratulations to @Mykalt45.

In his current role at ARTAN, his efforts are focused on driving forward the development of ARTAN-102. This initiative centers on an engineered tRNA designed to address a specific nonsense mutation, namely a scenario in which an arginine codon changes into a stop. This important scientific work also highlights VitaRNA, an endeavor that is proudly backed by the VitaDAO community.

Recent findings published in Nature Aging reveal a fascinating new dimension to brain stem cells. While it is common to view these structures merely as neuron production centers, the latest evidence demonstrates that they also shape cognitive abilities through a completely different pathway.

During laboratory studies involving mice, researchers discovered that stem cells within the hippocampus produce PLA2G7. This specific lipid enzyme functions by reducing inhibitory signaling. Once scientists eliminated the enzyme from these specific cells, the animal subjects displayed noticeably better cognitive performance. The results were particularly encouraging in older mice, where blocking PLA2G7 not only revived their inhibitory function but also led to similar cognitive enhancements.

It is worth noting that this research is still in its initial stages and has exclusively involved mice thus far. 🧠

http://nature.com/articles/s43587-026-01202-2

Backed by the VitaDAO community, the team from VitaRNA / ArtanBIO will be taking the stage tomorrow in St. Pete for the @spARKbyARK Innovation Showcase.

Leading the company are CEO @Bodeeeman, co-founder and COO @aschwartzphd, and co-founder and CSO @Mykalt45.

The group is currently advancing their lead program, ARTAN-102, through the preclinical phase. This initiative centers on a suppressor tRNA designed for a specific kind of nonsense mutation, precisely where an arginine codon converts into a stop codon.

A recent publication by Moreno et al. in the journal Aging Cell reveals that the biological process of autophagy does not merely decrease as we grow older. The researchers discovered that while the genes related to autophagy actually increased their activity in aging human skin cells, the observed cellular recycling rates failed to increase accordingly. Furthermore, the study examined a small group of individuals in the over-70s category and found that those with higher rates exhibited worse physical function. Consequently, these observations imply that this phenomenon is likely a physiological reaction to stress rather than a sign of improved cellular capacity. The full details of this research are available here: http://pubmed.ncbi.nlm.nih.gov/42802483/

At approximately 194 years of age, Jonathan the tortoise has survived about a century beyond the typical maximum lifespan for his species. A recent paper featured in Science Advances has mapped out his genome and methylome, bringing some fascinating biological insights to light.

When evaluated alongside other giant tortoises, Jonathan was found to carry distinct genetic variants throughout the majority of his aging pathways. Furthermore, researchers noted that the promoters for genes responsible for RNA processing and mitochondrial energy exhibited low-entropy, or low-noise, methylation.

According to the authors of the study, the exact regulation of these specific genes might play a crucial role in achieving such an extended lifespan. However, they are careful to point out that since this research is based on a single tortoise, the findings provide a promising lead rather than definitive proof.

http://science.org/doi/10.1126/sciadv.adw8887

Life Biosciences has just released the very first human data regarding ER-100, their partial epigenetic reprogramming gene therapy.

These early insights stem from an interim Phase 1 safety study evaluating the treatment for glaucoma. The trial is currently structured as an open-label investigation with no control arm. Out of the approximately 18 individuals planned for the overall project, three people have participated so far.

The preliminary safety profile is quite encouraging. The single dose administered to the participants was well tolerated through Day 56, with researchers reporting a complete absence of serious adverse events. Because of these favorable initial results, the safety board has recommended escalating the study to Dose Level 2.

Alongside the safety findings, researchers observed positive functional changes. For two of the three participants, 28 percent or more of their visual-field points demonstrated an improvement exceeding 4 dB.

For more details, you can view the official announcement at the link below.

http://lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/

Have you ever wondered what is required for the FDA to authorize a drug for aging? During the #ARDD2026 event, FDA officials provided their most straightforward responses to date regarding this process.

Chief Scientist Steven Kozlowski confirmed that the next regulatory science agenda for the agency will feature this subject, stating directly that "aging and longevity will be one of those topics."

Additionally, the representatives detailed two acceptable methods to demonstrate that a medication effectively slows aging. Developers can either show that a treatment offers benefits across several age-related conditions, or they can prove it leads to a slower decline in physical and mental capacity. They also indicated that the first approvable trials will likely be conducted with older, higher-risk people.

For an excellent summary of these developments, check out the nice write-up by Lifespan available here: http://lifespan.io/fda-leaders-name-longevity-a-priority-at-ardd/

Proudly backed by the VitaDAO community, the team at @Cyclarity recently presented some exciting news during #ARDD2026.

Their Phase 1a trials demonstrated that the therapy is well tolerated while successfully promoting the dose-dependent excretion of 7KC. Building on this momentum, the exact same 7KC target is now being evaluated for a second indication that extends well beyond atherosclerosis. Specifically, researchers discovered that combining UDP-003 with an existing FDA-approved agent significantly reduced liver fat accumulation in vivo, establishing a promising path toward addressing MASH.

You can explore the full scientific details and data by reading the abstract here: http://agingpharma.org/files/ARDD2026_Poster_Abstracts.pdf

Individuals in both the Bahamas and Montana are currently permitted to access experimental medications years in advance of standard regulatory approval. Within the longevity space, this development has completely shifted the conversation. We are no longer wondering if these treatments will become accessible. Instead, the pressing questions are who gets to use them, how safely they can be administered, and what the financial cost will be.

We are very interested in hearing your perspective on these issues. In partnership with LARTA and Wildcreek Life Sciences, we are hosting an anonymous survey that will only require 10 to 15 minutes of your time. We invite you to share your valuable feedback by following the link below.

https://docs.google.com/forms/d/e/1FAIpQLSflnN6mbjxfYAvKLvlII8kHVtr59L5Mpc6KbzyMafD_zgaTPQ/viewform

Exciting progress is being made in the treatment of androgenetic alopecia as Rubedo advances its compound RLS-1496. Backed by the VitaDAO community, this upcoming research represents the inaugural clinical trial of a GPX4 modulator designed specifically to address hair loss. Ex vivo studies measuring hair elongation against a vehicle control have already yielded promising results, with the maximum dosage demonstrating a growth trend that exceeded that of finasteride. The clinical trial is scheduled to commence in October 2026, and the resulting data is anticipated to be available during the first half of 2027. For further details, please visit https://www.businesswire.com/news/home/20260916811892/en/Rubedo-Life-Sciences-Announces-Clinical-Study-to-Treat-Hair-Loss-with-GPX4-Modulator-RLS-1496-First-Human-Ex-Vivo-Evidence-Demonstrates-Robust-Hair-Follicle-Growth

A historic milestone has just been reached in Japan, as the number of residents aged 100 or older has climbed to a record high of 107,677.

Seeing a growing number of individuals reach the age of 100 is absolutely wonderful news. However, it is equally important that these additional years of life are characterized by strong well-being and self-sufficiency. This core belief is exactly what motivates us to provide financial support for scientific research on the aging process.

https://www.nippon.com/en/news/yjj2026091500468/

Recent research suggests that managing damage to the blood-brain barrier might offer a new way to approach Alzheimer's disease. A newly published study has identified that an accumulation of fibronectin is connected to barrier deterioration linked with APOE4. During tests using experimental models, researchers found that bringing down fibronectin levels successfully returned the barrier to its proper function. At this point, though, investigations have not yet determined if this restoration will actually defend memory.

https://www.nature.com/articles/s43587-026-01204-0